Khiron Reports Revenue Growth Of 59.6% In 2021, Gross Profit Improves 230% YoY

Khiron Life Sciences Corp. KHRNF KHRN A released its financial results for the year ended and quarter ended December 31, 2021.

2021 Financial Highlights:

• Net loss of CA$33.13 million ($25.67 million) compared to net loss of CA$24,04 million in 2020, an unfavorable increase of 37.81%.

• Revenue of CA$12.8 million compared to CA$8.02 million in 2020

• Adjusted EBITDA was a loss of CA$17.38 million compared to a loss of CA$18.76 million in 2020.

• Gross profit before fair value adjustments was CA$4.91 million compared to CA$1.48 million in 2020, a favorable increase of 231.75%.

Q4 2021 Financial Highlights:

• Net loss of CA$19.5 million compared to net loss of CA$2.37 million in Q4 2020, an unfavorable increase of 722.78%.

• Revenue of CA$3.63 million compared to CA$2.52 million in Q4 2020

• Adjusted EBITDA was a loss of CA$5.65 million compared to a loss of CA$4.34 million in Q4 2020.

• Gross profit before fair value adjustments was CA$1.08 million compared to CA$402,000 in Q4 2020.

Related News

Cannabis Dispensary Roundup: Where To Buy Rec Marijuana In New Jersey, CBD Spas & More Store Openings

Khiron Opens New Zerenia Clinic And Medical Cannabis Pharmacy In Colombia

How Efficient Is Medicinal Cannabis As Treatment For Chronic Pain? Khiron's Clinical Study Reveals